IGC Pharma, Inc. (NYSE:IGC) shares made small progress Wednesday, on word its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).
The Potomac, Md.-based company says its trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.
To accelerate enrollment across all clinical sites, IGC Pharma has implemented an innovative recruitment campaign leveraging geofencing technology and digital outreach through social media platforms. The recruitment strategy was piloted at select trial sites, where it achieved a remarkable 200-300% increase in enrollment at a relatively low cost per lead. Building on this success, IGC Pharma is expanding the campaign to the other trial locations, with the goal of completing enrollment and the CALMA trial in the second half of 2025.
By combining advanced outreach tools with CALMA's clear focus, IGC aims to enhance engagement with patients and caregivers while advancing toward key milestones in Alzheimer's treatment development.
CEO Ram Mukunda commented, "Recruitment is one of the most significant challenges in Alzheimer's clinical trials, and our use of innovative geofencing technology, wherein we digitally target individuals living in a 15-25-mile radius of a clinical site, has delivered impressive results, achieving a significant outreach and enrollment at select sites.
IGC shares kicked off Wednesday’s trading up 0.04 cents, or 1.3%, to 35 cents.
